Using Clinical Research Results in Investor Communications
Clinical evidence can support responsible product positioning, marketing, and investor communications when claims remain faithful to study design, results, limitations, uncertainty, and applicable advertising and disclosure rules.
The Academy of Medical Sciences approaches clinical research through scientifically justified protocols, independent ethics oversight, participant protection, appropriate operations, data-quality controls, statistical analysis, and transparent reporting.
Study Results
Clinical data may be included in investor or IPO communications when material information is presented accurately and consistently with legal disclosure obligations. Evidence should not be exaggerated, and limitations, uncertainty, study status, and unfavorable findings may be material.
- Clinical data may be included in investor or IPO communications when material information is presented accurately and consistently with legal disclosure obligations. Evidence should not be exaggerated, and limitations, uncertainty, study status, and unfavorable findings may be material.
- Clinical data may be included in investor or IPO communications when material information is presented accurately and consistently with legal disclosure obligations. Evidence should not be exaggerated, and limitations, uncertainty, study status, and unfavorable findings may be material.
- Clinical data may be included in investor or IPO communications when material information is presented accurately and consistently with legal disclosure obligations. Evidence should not be exaggerated, and limitations, uncertainty, study status, and unfavorable findings may be material.
The Academy of Medical Sciences approaches clinical research through scientifically justified protocols, independent ethics oversight, participant protection, appropriate operations, data-quality controls, statistical analysis, and transparent reporting.
Study Results
Clinical data may be included in investor or IPO communications when material information is presented accurately and consistently with legal disclosure obligations. Evidence should not be exaggerated, and limitations, uncertainty, study status, and unfavorable findings may be material.
1. Clinical Research
The Academy of Medical Sciences approaches clinical research through scientifically justified protocols, independent ethics oversight, participant protection, appropriate operations, data-quality controls, statistical analysis, and transparent reporting.
2. Clinical Research
Clinical data may be included in investor or IPO communications when material information is presented accurately and consistently with legal disclosure obligations. Evidence should not be exaggerated, and limitations, uncertainty, study status, and unfavorable findings may be material.
3. Clinical Research
Clinical data may be included in investor or IPO communications when material information is presented accurately and consistently with legal disclosure obligations. Evidence should not be exaggerated, and limitations, uncertainty, study status, and unfavorable findings may be material.
Study Results
Clinical data may be included in investor or IPO communications when material information is presented accurately and consistently with legal disclosure obligations. Evidence should not be exaggerated, and limitations, uncertainty, study status, and unfavorable findings may be material.
1. Data Management
The Academy of Medical Sciences approaches clinical research through scientifically justified protocols, independent ethics oversight, participant protection, appropriate operations, data-quality controls, statistical analysis, and transparent reporting.
2. Study Results
Clinical data may be included in investor or IPO communications when material information is presented accurately and consistently with legal disclosure obligations. Evidence should not be exaggerated, and limitations, uncertainty, study status, and unfavorable findings may be material.
3. Clinical Research
Clinical data may be included in investor or IPO communications when material information is presented accurately and consistently with legal disclosure obligations. Evidence should not be exaggerated, and limitations, uncertainty, study status, and unfavorable findings may be material.
Conclusion
The Academy of Medical Sciences approaches clinical research through scientifically justified protocols, independent ethics oversight, participant protection, appropriate operations, data-quality controls, statistical analysis, and transparent reporting.
